School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Protein Expr Purif. 2024 Jan;213:106362. doi: 10.1016/j.pep.2023.106362. Epub 2023 Sep 7.
Homo sapiens adenosine deaminase isoform 1 (HsADA1) hydrolyzes adenosine and 2-deoxyadenosine as a key step in the purine nucleoside salvage pathway. Some HsADA1 mutations have severe deleterious effects, as is the case in a severe combined immunodeficiency resulting from loss of enzyme activity (ADA-SCID). Other mutations that reduce enzyme activity, for instance the Asp8Asn (D8N) variant, do not cause ADA-SCID but are correlated with other consequences to health. To ease further study of HsADA1 and its variants, we optimized an inexpensive, recombinant expression process in an Escherichia coli host through multiplexed parameter testing enabled by a lysate-based microtiter plate assay. We demonstrate the importance of gene codon usage, induction time and temperature, and alcohol supplementation towards improving enzyme yield to a final titer of 5 mg per liter of culture. We further show that use of a double-histidine-tag (his-tag) system greatly improves purity. We then utilize our expression and purification framework to produce the HsADA1 D8N variant, which had previously not been purified to homogeneity. We confirm that the D8N variant is ∼30% less active than the wildtype HsADA1 and show that it better retains its activity in human serum. Additionally, we show that both HsADA1 and the D8N variant have heightened activity in serum, driven in part by a previously undescribed phenomenon involving albumin. Therefore, this work presents a valuable process to produce HsADA1 that allows for insights into it and its variants' behavior. We also confirm the utility of lysate-based activity assays towards finding optimal E. coli expression conditions for enzymes and show how fusing his-tags in tandem can enhance product purity.
人类腺苷脱氨酶同工酶 1(HsADA1)作为嘌呤核苷补救途径中的关键步骤,可水解腺苷和 2-脱氧腺苷。一些 HsADA1 突变具有严重的有害影响,例如由于酶活性丧失导致的严重联合免疫缺陷(ADA-SCID)。其他降低酶活性的突变,例如天冬氨酸 8 到天冬酰胺(D8N)的突变,不会导致 ADA-SCID,但与其他健康后果相关。为了方便进一步研究 HsADA1 及其变体,我们通过基于裂解物的微量滴定板测定法实现了基于裂解物的微量滴定板测定法,对大肠杆菌宿主中的廉价、重组表达过程进行了多参数测试优化。我们证明了基因密码子用法、诱导时间和温度以及酒精补充对提高酶产量的重要性,最终达到每升培养物 5 毫克的终浓度。我们进一步表明,使用双组氨酸标签(his-tag)系统可以大大提高纯度。然后,我们利用我们的表达和纯化框架来生产以前未达到均相的 HsADA1 D8N 变体。我们确认 D8N 变体的活性比野生型 HsADA1 低约 30%,并且在人血清中更好地保持其活性。此外,我们表明 HsADA1 和 D8N 变体在血清中均具有更高的活性,部分原因是涉及白蛋白的以前未描述的现象。因此,这项工作提供了一种有价值的生产 HsADA1 的方法,使我们能够深入了解其及其变体的行为。我们还确认了基于裂解物的活性测定法在寻找最佳大肠杆菌表达条件方面的用途,用于酶,并表明如何串联融合 his-tags 可以提高产品纯度。